iLite® mTNF-alpha (-) Target

BM5014

A control cell line lacking membrane-bound TNF-alpha, used for specificity assessment in TNF-targeted assays.

  • "Assay-ready" format for rapid and convenient use
  • Reproducible and biologically relevant results
  • Reduced assay variability and higher reproducibility compared to cells in culture
Add to quote
iLite® mTNF-alpha (-) Target

Product Overview

iLite® Target mTNF-alpha (-) Assay Ready Cells are human cells based on the embryonic kidney cell line, HEK293. They have been genetically engineered and optimized to deplete all expression of the surface protein mTNF-alpha.

These cells are for use as internal controls for unspecific activation of ADCC and ADCP, which can be a confounding factor when performing ADCC and ADCP assays. They can also be used for adjusting background levels when analyzing serum samples, effectively removing any issues with varying background between samples

iLite® Target mTNF-alpha (-) Assay Ready Cells are optimized to be used together with iLite® ADCC and ADCP Effector Assay Ready Cells and iLite® Target mTNF-alpha (+) Assay Ready Cells for measuring the ADCC and ADCP activity of anti-TNF-alpha antibodies.

FOR RESEARCH USE ONLY

How it works

arrow
Principle of iLite® ADCC and ADCP Bioassays

Principle of iLite® ADCC and ADCP Bioassays

Our two-cell ADCC or ADCP bioassays consist of target cells expressing the antigen under study and effector cells closely resembling the natural FcγRIIIa (for ADCC) or FcγRIIa (for ADCP) signal transduction pathway. Target control cells that do not express the antigen are also available. The effector cells contain two luciferase genes: an inducible Firefly luciferase gene and a constitutively expressed Renilla luciferase gene used for control purposes.

Principle of iLite® ADCC and ADCP Bioassays

Principle of iLite® ADCC and ADCP Bioassays

A therapeutic antibody can bind to its antigen on the target cell surface. The fc-region of the antibody can bind to the FcγRIIIa (ADCC) or FcγRIIa (ADCP) receptor on the effector cells.

Principle of iLite® ADCC and ADCP Bioassays

Principle of iLite® ADCC and ADCP Bioassays

The antibody binding to the target and effector cells triggers a signal pathway in the effector cell, activating the Firefly luciferase gene. The strength of the resulting luciferase luminescence correlates with the antibody’s ability to activate ADCC or ADCP.

arrow

What's in the box?

>250 µL of iLite® Assay Ready Cells suspended in cryoprotective medium from Gibco (cat no 12648-010).

Specifications

Product code BM5014
Assay target ADCC ADCP mTNF-alpha
Size 1 vial corresponding to one 96 well plate
Technology Cell-based reporter gene assay
Detection system Luminescence
Regulatory status Research Use Only

Documents

Performance Data

Performance Data

expand
Product Specification

Product Specification

expand
SDS

Safety Data Sheet

expand
Scientific Posters

Scientific Posters

expand
Technical Note

Technical Note

expand